Burcu Cil Yılmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Burcu Cil Yılmaz has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Sibel Kaplan Sarikavak
Department of Pediatric Allergy and Immunology, University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Istanbul, Türkiye
4 shared publications Cigdem Aydogmus
3 shared publicationsErkan Cakmak
3 shared publications- Pınar Gökmirza Özdemir
Basaksehir Cam and Sakura City Hospital
3 shared publications - Özge Türkyılmaz Uçar
Basaksehir Cam and Sakura City Hospital, Pediatric Immunology and Allergy University of Health Sciences Istanbul Türkiye
3 shared publications - Ahmet Sert
Department of Pediatric Allergy and Clinical Immunology Başakşehir Çam and Sakura City Hospital İstanbul Türkiye
2 shared publications
Latest Publications
- 1 July 2026
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 104 (1) , e70133
Recent Thymic Emigrant Levels in Inborn Errors of Immunity: Is Their Diagnostic Value Greater Than We Think?
We aimed to evaluate the sensitivity and specificity of Recent Thymic Emigrant (RTE) levels for diagnostic discrimination among various Inborn Errors of Immunity (IEI) subgroups. We analysed 205 paediatric patients diagnosed with IEI at the Paediatric Immunology and Allergy Department of Başakşehir Çam and Sakura City Hospital in Istanbul between January 2021 and January 2024. An age‐ and sex‐matched control group consisting of 31 healthy children was also included for comparison. Demographic, clinical and laboratory data were evaluated. Reduced RTE levels were identified in 39% of all patients. Low RTE levels were most pronounced in patients with syndromic combined immunodeficiency (77%) and immune dysregulation (100%), and were also observed at high frequencies in combined immunodeficiency (CID) (60%) and autoinflammatory disorders (57.1%). For the syndromic CID group, the diagnostic performance of RTE yielded an area under the curve (AUC) of 0.80, with a sensitivity of 92% and a specificity of 52%. In the immune dysregulation group, the AUC was 0.79, with a sensitivity of 83.5% and a specificity of 57.1%. Assessment of RTE levels represents a valuable diagnostic biomarker, particularly for patients within the syndromic CID and immune dysregulation categories. This parameter may contribute meaningfully to clinical practice by facilitating early diagnosis, guiding genetic testing and enabling assessment of thymic function. Incorporating thymic output assessment into routine immunophenotyping panels may shorten the diagnostic timeline for IEI and allow earlier initiation of appropriate therapies.
- 1 July 2026
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 104 (1) , e70133
Recent Thymic Emigrant Levels in Inborn Errors of Immunity: Is Their Diagnostic Value Greater Than We Think?
We aimed to evaluate the sensitivity and specificity of Recent Thymic Emigrant (RTE) levels for diagnostic discrimination among various Inborn Errors of Immunity (IEI) subgroups. We analysed 205 paediatric patients diagnosed with IEI at the Paediatric Immunology and Allergy Department of Başakşehir Çam and Sakura City Hospital in Istanbul between January 2021 and January 2024. An age‐ and sex‐matched control group consisting of 31 healthy children was also included for comparison. Demographic, clinical and laboratory data were evaluated. Reduced RTE levels were identified in 39% of all patients. Low RTE levels were most pronounced in patients with syndromic combined immunodeficiency (77%) and immune dysregulation (100%), and were also observed at high frequencies in combined immunodeficiency (CID) (60%) and autoinflammatory disorders (57.1%). For the syndromic CID group, the diagnostic performance of RTE yielded an area under the curve (AUC) of 0.80, with a sensitivity of 92% and a specificity of 52%. In the immune dysregulation group, the AUC was 0.79, with a sensitivity of 83.5% and a specificity of 57.1%. Assessment of RTE levels represents a valuable diagnostic biomarker, particularly for patients within the syndromic CID and immune dysregulation categories. This parameter may contribute meaningfully to clinical practice by facilitating early diagnosis, guiding genetic testing and enabling assessment of thymic function. Incorporating thymic output assessment into routine immunophenotyping panels may shorten the diagnostic timeline for IEI and allow earlier initiation of appropriate therapies.
- Open Access
- 19 June 2026
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 46 (1)
Disseminated Tuberculosis and Early-Onset SLE in a Child with a Novel STAT1 Gain-of-Function Mutation: a Case Report
Gain-of-function (GOF) mutations in the STAT1 gene result in heightened interferon signaling and impaired IL-17 immunity. While chronic mucocutaneous candidiasis (CMC) remains the hallmark feature, affected individuals often display a broader phenotype including viral infections, mycobacterial susceptibility, and autoimmune diseases. We describe a 4-year-old girl who initially presented with abdominal pain and was diagnosed with acute appendicitis. During surgery, marked mesenteric lymphadenopathy was discovered, and histopathology revealed acid-fast bacilli. Mycobacterium tuberculosis was confirmed by gastric fluid PCR, prompting initiation of anti-tuberculosis therapy. Her past medical history included hospitalization for herpes zoster and recurrent episodes of oral candidiasis during febrile illnesses. Immunologic evaluation showed normal immunoglobulin levels, vaccine responses, oxidative burst, and lymphocyte proliferation. However, low NK cells, reduced recent thymic emigrants, and decreased class-switched memory B cells were noted. Genetic testing revealed a previously unreported heterozygous STAT1 variant (p.Thr387Arg), classified as likely pathogenic according to ACMG criteria with a CADD score of 23.4. Parental genetic testing was negative, suggesting a de novo mutation. Although STAT1 phosphorylation could not be assessed, the proportion of IL-17–producing CD4⁺ T cells was markedly reduced, supporting impaired Th17 immunity. Based on clinical, immunologic, and genetic findings, a clinical and immunological phenotype consistent with STAT1 GOF was established. One year later, the patient developed arthritis and was diagnosed with systemic lupus erythematosus (SLE) based on autoantibody positivity and low complement levels. During follow-up, she also developed hemophagocytic lymphohistiocytosis (HLH), further reflecting severe immune dysregulation. Ruxolitinib was initiated as bridging therapy, resulting in partial clinical improvement, and hematopoietic stem cell transplantation (HSCT) was planned as definitive therapy. This report describes a novel STAT1 variant consistent with a gain-of-function phenotype associated with disseminated tuberculosis and early-onset SLE, expanding the clinical and molecular spectrum of this disorder. In children presenting with overlapping infectious and autoimmune features, underlying inborn errors of immunity should be considered. The online version contains supplementary material available at 10.1007/s10875-026-02040-y.
- 19 June 2026
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 46 (1)
Open AccessDisseminated Tuberculosis and Early-Onset SLE in a Child with a Novel STAT1 Gain-of-Function Mutation: a Case Report
Gain-of-function (GOF) mutations in the STAT1 gene result in heightened interferon signaling and impaired IL-17 immunity. While chronic mucocutaneous candidiasis (CMC) remains the hallmark feature, affected individuals often display a broader phenotype including viral infections, mycobacterial susceptibility, and autoimmune diseases. We describe a 4-year-old girl who initially presented with abdominal pain and was diagnosed with acute appendicitis. During surgery, marked mesenteric lymphadenopathy was discovered, and histopathology revealed acid-fast bacilli. Mycobacterium tuberculosis was confirmed by gastric fluid PCR, prompting initiation of anti-tuberculosis therapy. Her past medical history included hospitalization for herpes zoster and recurrent episodes of oral candidiasis during febrile illnesses. Immunologic evaluation showed normal immunoglobulin levels, vaccine responses, oxidative burst, and lymphocyte proliferation. However, low NK cells, reduced recent thymic emigrants, and decreased class-switched memory B cells were noted. Genetic testing revealed a previously unreported heterozygous STAT1 variant (p.Thr387Arg), classified as likely pathogenic according to ACMG criteria with a CADD score of 23.4. Parental genetic testing was negative, suggesting a de novo mutation. Although STAT1 phosphorylation could not be assessed, the proportion of IL-17–producing CD4⁺ T cells was markedly reduced, supporting impaired Th17 immunity. Based on clinical, immunologic, and genetic findings, a clinical and immunological phenotype consistent with STAT1 GOF was established. One year later, the patient developed arthritis and was diagnosed with systemic lupus erythematosus (SLE) based on autoantibody positivity and low complement levels. During follow-up, she also developed hemophagocytic lymphohistiocytosis (HLH), further reflecting severe immune dysregulation. Ruxolitinib was initiated as bridging therapy, resulting in partial clinical improvement, and hematopoietic stem cell transplantation (HSCT) was planned as definitive therapy. This report describes a novel STAT1 variant consistent with a gain-of-function phenotype associated with disseminated tuberculosis and early-onset SLE, expanding the clinical and molecular spectrum of this disorder. In children presenting with overlapping infectious and autoimmune features, underlying inborn errors of immunity should be considered. The online version contains supplementary material available at 10.1007/s10875-026-02040-y.
- 9 April 2026
- Published by S. Karger AG in International Archives of Allergy and Immunology
- p. 1-13
Pediatric Severe Cutaneous Adverse Drug Reactions: Clinical Characteristics and Comparison of Causality Assessment Tools and Severity Scoring Systems in Relation to Clinical Outcomes from a Single-Center Experience
Introduction: Severe cutaneous adverse reactions (SCARs) such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) are rare but life-threatening in children. Pediatric data on causative drugs, immunologic features, and outcomes remain limited. Therefore, this study aimed to compare clinical, laboratory, and immunologic findings, as well as causality assessment tools and severity scoring systems, in pediatric patients with DRESS and SJS/TEN. Methods: We retrospectively analyzed 23 children (<18 years) with SCAR at a tertiary center (December 2022–April 2025). DRESS and SJS/TEN were diagnosed using RegiSCAR and consensus criteria, respectively. Causality was evaluated by the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) and Naranjo algorithms for DRESS and the algorithm of drug causality in epidermal necrolysis (ALDEN) for SJS/TEN. Disease severity in DRESS was evaluated using both the Mizukawa severity score and the EAACI 2025 Pediatric Position Paper (PP) severity grading, while SJS/TEN severity was assessed using Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN). Clinical features, laboratory findings, treatment strategies, and outcomes were compared. Results: DRESS constituted 69.6% of cases. Antibiotics predominated in DRESS (68.7%), and antiepileptics predominated in SJS/TEN (57.1%). Causality assessment yielded predominantly probable classifications in DRESS (69.2%), while aromatic anticonvulsants scored very probable in SJS/TEN by ALDEN and severity grading aligned with clinical outcomes. In DRESS patients, severity stratification by the Mizukawa score predominantly classified cases as moderate, guiding systemic corticosteroid use. When reclassified according to the EAACI 2025 PP grading, several patients with limited extra-hepatic involvement were upgraded to higher severity categories, despite favorable clinical response to corticosteroid monotherapy. In SJS/TEN, SCORTEN scores aligned with overall clinical severity but did not correlate with ocular involvement. Intravenous immunoglobulin was administered more frequently in SJS/TEN than in DRESS (85.7% vs. 12.5%, p = 0.001). No mortality occurred. During follow-up, immune-mediated complications were observed exclusively in the DRESS group, including autoimmune thyroiditis in 1 patient, autoimmune thyroiditis with concurrent autoimmune neutropenia in another, and chronic urticaria in 1 patient, whereas no immune-mediated sequelae were detected in the SJS/TEN group. Conclusion: Pediatric DRESS and SJS/TEN display distinct clinical, immunologic, and severity profiles. Early cluster of differentiation 19-positive B-cell lymphopenia appears characteristic of DRESS and may support severity stratification and long-term autoimmune surveillance. Comparative application of the Mizukawa score and EAACI 2025 PP grading highlights potential differences in severity classification that may influence treatment decisions. Integrating standardized causality and severity tools may improve phenotype-specific management of pediatric SCARs.
- 9 April 2026
- Published by S. Karger AG in International Archives of Allergy and Immunology
- p. 1-13
Pediatric Severe Cutaneous Adverse Drug Reactions: Clinical Characteristics and Comparison of Causality Assessment Tools and Severity Scoring Systems in Relation to Clinical Outcomes from a Single-Center Experience
Introduction: Severe cutaneous adverse reactions (SCARs) such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) are rare but life-threatening in children. Pediatric data on causative drugs, immunologic features, and outcomes remain limited. Therefore, this study aimed to compare clinical, laboratory, and immunologic findings, as well as causality assessment tools and severity scoring systems, in pediatric patients with DRESS and SJS/TEN. Methods: We retrospectively analyzed 23 children (<18 years) with SCAR at a tertiary center (December 2022–April 2025). DRESS and SJS/TEN were diagnosed using RegiSCAR and consensus criteria, respectively. Causality was evaluated by the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) and Naranjo algorithms for DRESS and the algorithm of drug causality in epidermal necrolysis (ALDEN) for SJS/TEN. Disease severity in DRESS was evaluated using both the Mizukawa severity score and the EAACI 2025 Pediatric Position Paper (PP) severity grading, while SJS/TEN severity was assessed using Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN). Clinical features, laboratory findings, treatment strategies, and outcomes were compared. Results: DRESS constituted 69.6% of cases. Antibiotics predominated in DRESS (68.7%), and antiepileptics predominated in SJS/TEN (57.1%). Causality assessment yielded predominantly probable classifications in DRESS (69.2%), while aromatic anticonvulsants scored very probable in SJS/TEN by ALDEN and severity grading aligned with clinical outcomes. In DRESS patients, severity stratification by the Mizukawa score predominantly classified cases as moderate, guiding systemic corticosteroid use. When reclassified according to the EAACI 2025 PP grading, several patients with limited extra-hepatic involvement were upgraded to higher severity categories, despite favorable clinical response to corticosteroid monotherapy. In SJS/TEN, SCORTEN scores aligned with overall clinical severity but did not correlate with ocular involvement. Intravenous immunoglobulin was administered more frequently in SJS/TEN than in DRESS (85.7% vs. 12.5%, p = 0.001). No mortality occurred. During follow-up, immune-mediated complications were observed exclusively in the DRESS group, including autoimmune thyroiditis in 1 patient, autoimmune thyroiditis with concurrent autoimmune neutropenia in another, and chronic urticaria in 1 patient, whereas no immune-mediated sequelae were detected in the SJS/TEN group. Conclusion: Pediatric DRESS and SJS/TEN display distinct clinical, immunologic, and severity profiles. Early cluster of differentiation 19-positive B-cell lymphopenia appears characteristic of DRESS and may support severity stratification and long-term autoimmune surveillance. Comparative application of the Mizukawa score and EAACI 2025 PP grading highlights potential differences in severity classification that may influence treatment decisions. Integrating standardized causality and severity tools may improve phenotype-specific management of pediatric SCARs.
- Open Access
- 25 February 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (2) , e70384
Clinical Spectrum of Cutaneous, Ocular, and Hair Manifestations in Patients With Inborn Errors of Immunity: Insights From a Single Center in Turkey
Background: Inborn errors of immunity (IEI), previously referred to as primary immunodeficiencies, are a heterogeneous group of genetic disorders affecting immune development and function. While once considered rare, IEIs are increasingly recognized, particularly in regions with high consanguinity rates. Cutaneous manifestations, as well as ocular and hair abnormalities, may provide early and clinically relevant diagnostic clues. This study aimed to assess the prevalence, types, and diagnostic value of cutaneous, ocular and hair manifestations in patients with IEI. Methods: A total of 386 patients with confirmed IEI, classified according to the 2024 IUIS criteria, were retrospectively analyzed. Cutaneous, ocular (e.g., conjunctivitis, keratitis, scleral telangiectasia), and hair manifestations (e.g., alopecia areata, pigmentary abnormalities) were systematically reviewed from medical records. Skin findings were categorized as infectious, immune‐allergic (eczema, alopecia areata, urticaria, erythroderma), disease‐specific, or other. Results: Cutaneous, ocular, and/or hair manifestations were identified in 198 patients (51.3%), with 59.1% present at diagnosis. Infectious manifestations were the most common (71.8%), followed by immune‐allergic findings (34.8%), including eczema (30.3%), and disease‐specific manifestations (17.7%). Ocular findings were observed in 15.7% of patients, while hair abnormalities were present in 4.04%. Skin infections were predominantly bacterial (53.1%) and were most frequent in phagocytic and innate immunity defects. Eczema was most frequent in hyper‐IgE syndrome (85.8%), while non‐eczematous allergic findings were most common in immune dysregulation. Ocular involvement, including viral retinitis and scleral telangiectasia, and hair abnormalities, such as syndromic hair shaft defects and alopecia areata, were observed across multiple IEI subgroups. Conclusion: Cutaneous, ocular, and hair abnormalities are frequent in IEI and may support early diagnosis. Recognition of recurrent, atypical, or treatment‐resistant skin, eye, or hair findings should prompt immunological evaluation, particularly in pediatric patients.
- 25 February 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (2) , e70384
Open AccessClinical Spectrum of Cutaneous, Ocular, and Hair Manifestations in Patients With Inborn Errors of Immunity: Insights From a Single Center in Turkey
Background: Inborn errors of immunity (IEI), previously referred to as primary immunodeficiencies, are a heterogeneous group of genetic disorders affecting immune development and function. While once considered rare, IEIs are increasingly recognized, particularly in regions with high consanguinity rates. Cutaneous manifestations, as well as ocular and hair abnormalities, may provide early and clinically relevant diagnostic clues. This study aimed to assess the prevalence, types, and diagnostic value of cutaneous, ocular and hair manifestations in patients with IEI. Methods: A total of 386 patients with confirmed IEI, classified according to the 2024 IUIS criteria, were retrospectively analyzed. Cutaneous, ocular (e.g., conjunctivitis, keratitis, scleral telangiectasia), and hair manifestations (e.g., alopecia areata, pigmentary abnormalities) were systematically reviewed from medical records. Skin findings were categorized as infectious, immune‐allergic (eczema, alopecia areata, urticaria, erythroderma), disease‐specific, or other. Results: Cutaneous, ocular, and/or hair manifestations were identified in 198 patients (51.3%), with 59.1% present at diagnosis. Infectious manifestations were the most common (71.8%), followed by immune‐allergic findings (34.8%), including eczema (30.3%), and disease‐specific manifestations (17.7%). Ocular findings were observed in 15.7% of patients, while hair abnormalities were present in 4.04%. Skin infections were predominantly bacterial (53.1%) and were most frequent in phagocytic and innate immunity defects. Eczema was most frequent in hyper‐IgE syndrome (85.8%), while non‐eczematous allergic findings were most common in immune dysregulation. Ocular involvement, including viral retinitis and scleral telangiectasia, and hair abnormalities, such as syndromic hair shaft defects and alopecia areata, were observed across multiple IEI subgroups. Conclusion: Cutaneous, ocular, and hair abnormalities are frequent in IEI and may support early diagnosis. Recognition of recurrent, atypical, or treatment‐resistant skin, eye, or hair findings should prompt immunological evaluation, particularly in pediatric patients.
- Open Access
- 1 February 2026
- Vol. 14 (2) , e70384
Clinical Spectrum of Cutaneous, Ocular, and Hair Manifestations in Patients With Inborn Errors of Immunity: Insights From a Single Center in Turkey.
Inborn errors of immunity (IEI), previously referred to as primary immunodeficiencies, are a heterogeneous group of genetic disorders affecting immune development and function. While once considered rare, IEIs are increasingly recognized, particularly in regions with high consanguinity rates. Cutaneous manifestations, as well as ocular and hair abnormalities, may provide early and clinically relevant diagnostic clues. This study aimed to assess the prevalence, types, and diagnostic value of cutaneous, ocular and hair manifestations in patients with IEI. A total of 386 patients with confirmed IEI, classified according to the 2024 IUIS criteria, were retrospectively analyzed. Cutaneous, ocular (e.g., conjunctivitis, keratitis, scleral telangiectasia), and hair manifestations (e.g., alopecia areata, pigmentary abnormalities) were systematically reviewed from medical records. Skin findings were categorized as infectious, immune-allergic (eczema, alopecia areata, urticaria, erythroderma), disease-specific, or other. Cutaneous, ocular, and/or hair manifestations were identified in 198 patients (51.3%), with 59.1% present at diagnosis. Infectious manifestations were the most common (71.8%), followed by immune-allergic findings (34.8%), including eczema (30.3%), and disease-specific manifestations (17.7%). Ocular findings were observed in 15.7% of patients, while hair abnormalities were present in 4.04%. Skin infections were predominantly bacterial (53.1%) and were most frequent in phagocytic and innate immunity defects. Eczema was most frequent in hyper-IgE syndrome (85.8%), while non-eczematous allergic findings were most common in immune dysregulation. Ocular involvement, including viral retinitis and scleral telangiectasia, and hair abnormalities, such as syndromic hair shaft defects and alopecia areata, were observed across multiple IEI subgroups. Cutaneous, ocular, and hair abnormalities are frequent in IEI and may support early diagnosis. Recognition of recurrent, atypical, or treatment-resistant skin, eye, or hair findings should prompt immunological evaluation, particularly in pediatric patients.
- 1 February 2026
- Vol. 14 (2) , e70384
Open AccessClinical Spectrum of Cutaneous, Ocular, and Hair Manifestations in Patients With Inborn Errors of Immunity: Insights From a Single Center in Turkey.
Inborn errors of immunity (IEI), previously referred to as primary immunodeficiencies, are a heterogeneous group of genetic disorders affecting immune development and function. While once considered rare, IEIs are increasingly recognized, particularly in regions with high consanguinity rates. Cutaneous manifestations, as well as ocular and hair abnormalities, may provide early and clinically relevant diagnostic clues. This study aimed to assess the prevalence, types, and diagnostic value of cutaneous, ocular and hair manifestations in patients with IEI. A total of 386 patients with confirmed IEI, classified according to the 2024 IUIS criteria, were retrospectively analyzed. Cutaneous, ocular (e.g., conjunctivitis, keratitis, scleral telangiectasia), and hair manifestations (e.g., alopecia areata, pigmentary abnormalities) were systematically reviewed from medical records. Skin findings were categorized as infectious, immune-allergic (eczema, alopecia areata, urticaria, erythroderma), disease-specific, or other. Cutaneous, ocular, and/or hair manifestations were identified in 198 patients (51.3%), with 59.1% present at diagnosis. Infectious manifestations were the most common (71.8%), followed by immune-allergic findings (34.8%), including eczema (30.3%), and disease-specific manifestations (17.7%). Ocular findings were observed in 15.7% of patients, while hair abnormalities were present in 4.04%. Skin infections were predominantly bacterial (53.1%) and were most frequent in phagocytic and innate immunity defects. Eczema was most frequent in hyper-IgE syndrome (85.8%), while non-eczematous allergic findings were most common in immune dysregulation. Ocular involvement, including viral retinitis and scleral telangiectasia, and hair abnormalities, such as syndromic hair shaft defects and alopecia areata, were observed across multiple IEI subgroups. Cutaneous, ocular, and hair abnormalities are frequent in IEI and may support early diagnosis. Recognition of recurrent, atypical, or treatment-resistant skin, eye, or hair findings should prompt immunological evaluation, particularly in pediatric patients.